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Summary LM985 is one of a series of compounds based on the flavone ring structure and selected for
clinical trial primarily for its activity in colon 38 as part of the NCI screen. We have investigated the anti-
tumour activity against three differing transplantable adenocarcinomas of the mouse colon (MAC). Single i.p.
injection at maximum tolerated dose showed no activity against the ascitic tumour MAC 15A, moderate
activity against subcutaneous tumours MAC 13 and MAC 15A and produced a significant growth delay
against MAC 26. These responses against s.c. tumours were considerably enhanced by repeated injection 7
days later when >90% tumour inhibition was seen in MAC 13 and cures were achieved in MAC 26.
Pharmacokinetic studies confirm the rapid degradation of LM985 to LM975, the possible active principle.
Analysis of area under the curve for LM975 indicated a good relationship with administered doses of LM985
and tumour responses. The MAC system shows a good correlation with human large bowel cancer and these
preliminary observations with LM985 would suggest that it or its metabolite LM975 may have a value in the
management of large bowel cancer.
Oxo-4 phenyl-2,4,H-1 Benzopyranne-8-yl-acetate of
dimethylamino-2-ethyl, chlorhydrate (LM985) is the
ester of flavone acetic acid and dimethylethanol-
amine which was submitted to the NCI for pre-
clinical screening in 1980. It was selected for clinical
trial largely for its activity against colon 38.
Animal toxicology indicated that LM985 did not
cause myelosuppression, nausea or vomiting or
major organ toxicity. Lethal doses caused clonic
spasms, stupor and death (Kerr et al., personal
communication). The mechanism of action is not
known but flavonoids are capable of binding to
DNA and a variety of intracellular enzymes bearing
metal ions (Havsteen, 1983). Kerr et al. (1985) have
suggested that the hydrolysis product LM975 may
be the active principle (Figure 1).
The mouse adenocarcinoma of the colon (MAC)
series of transplantable tumours (Double et al.,
1975) has been used in a variety of chemotherapy
studies. Histologically the MAC tumours are
similar to human colon cancer (Cowen et al., 1980)
and Double & Ball (1975) have demonstrated that
the spectrum of chemotherapeutic sensitivity
showed good correlation with the response rates of
standard therapeutic agents against large bowel
cancer. Definite anti-tumour activity is seen only at
dose levels close to the maximum tolerated dose
indicating the general insensitivity of the tumour
system.
The present study investigates the anti-tumour










Figure 1 Structural formulae of (A) LM985 and (B)
LM975.
different histology, growth characteristics and
spectra of chemosensitivity to standard agents and
relates anti-tumour response to pharmacokinetics.
Materials and methods
Animals
Pure strain NMRI mice (age 6-8 weeks) from our
inbred colony were used. They were fed on CRM
diet (Labsure, England) and water ad libitum.
Tumour system
The development of several adenocarcinomata of
the large bowel in mice from primary tumours
induced by prolonged administration of 1,2-
dimethylhydrazine has been described elsewhere
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(Double et al., 1975). MAC 13 tumours were trans-
planted into female mice and MAC 26 tumours
into male mice, by s.c. implantation of tumour
fragments (- 1 x 2mm) in the flank. MAC 15A
ascites tumours were transplanted into male mice
by i.p. inoculation of 1 x 106 tumour cells in 0.2ml
physiological saline. This inoculation gives a
survival time of - 14 days. MAC 15A cells were
also inoculated s.c. into further groups of mice.
Test compounds
LM985 was received from the NCI via the EORTC
Screening and Pharmacology Group and further
supplies via Dr W.R. Vezin, CRC Formulation
Unit, University of Strathclyde. LM975 was a gift
from Lipha Lyonnaise Industrielle Pharmaceutique,
Lyons via Professor S.B. Kaye, University of
Glasgow. Positive control compounds methyl-
CCNU and cyclophosphamide were gifts from the
NCI and Boehringer, UK respectively. LM985 and
cyclophosphamide were dissolved in physiological
saline and Methyl-CCNU in 10% ethanol/arachis
oil at an appropriate concentration, for a desired
dose to be administered in 0.1 ml/l0 g body weight.
All injections were i.p.
Chemotherapy
Animals bearing s.c. tumours were allocated by
restricted randomisation into groups of 10 and
those bearing MAC 15A ascites tumours were
allocated into groups of 5. With the more rapidly
growing MAC 13 and 15A tumours, chemotherapy
commenced 2 days after implantation. MAC 13
and MAC 15A s.c. tumours are palpable at this
stage and anti-tumour responses were assessed 14
days later by recording tumour weights. MAC 15A
i.p. tumours were assessed from median survival
times (MST) (Geran et al., 1972). With the slower
growing MAC 26 tumours chemotherapy did not
commence until tumours could be reliably
measured i.e. until they achieved minimum tumour
volumes of 40cm3. MAC 26 was assessed by twice
weekly two-dimensional caliper measurements of
the tumour. Tumour volume was calculated from
the formula a2 x b/2 where a is the smaller diameter
and b is the larger (Geran et al., 1972). Tumour
volumes were normalised with respect to starting
volumes and graphs of relative tumour volume
against time were plotted on semi-log graph paper.
Activity scores of LM985 and positive control
compounds against each tumour line were allocated
as shown in Table I.
Reagents
Spectroscopic grade ethanol (BDH Chemicals,
Poole, Dorset), p-dimethylaminobenzaldehyde
Table I System for scoring anti-tumour activity
Solid s.c. tumours MAC 15A (ascitic tumour)
% inhibition' Score TIC%b Score
<25 0 < 125 0
25-49 1 + 125-149 +
50-74 2+ 150-200 1+
75-90 3+ >200 2+
>90 4+ <50% cures 3+
>50% cures 4+
aSolid tumours assessed by weight or volume
inhibition; bMST of treated animals over MST of
control animals x 100.
(Sigma Chemical Co., Poole, Dorset) and triple
distilled water were used. Other reagents were of
analytical grade. Time expired blood was obtained
from the Haematology Department, Bradford
Royal Infirmary. The blood was centrifuged at
2000g for 15min and the separated plasma stored
at -20°C.
Sample extraction and analysis
Blood samples from three mice at each time point
were taken by cardiac puncture under ether
anaesthesia and collected into heparinised tubes and
centrifuged at 2000g and 4°C for 10min. The
plasma was frozen and stored at -20°C until
analysis.
LM985 and LM975 were extracted from plasma
using solid phase chromatography. Plasma samples
(50pl) were mixed with 0.5ml sodium acetate-acetic
acid buffer (0.1M, pH4.0) (acetate buffer) and the
internal standard (p-dimethylaminobenzaldehyde)
added (100yl at 100 sgml -1). Bond-Elut cartridges
containing particles of C18-coated silica (Analyti-
chem International) were activated by passing
ethanol (1 ml) then acetate buffer (1 ml) through
under negative pressure using the Vac-Elut system
(Analytichem International). Plasma specimens were
applied to the Bond-Elut cartridges. The cartridges
were then washed with buffer and air dried. Ethanol
(400p1) was passed through the cartridges and the
elutents collected in tapered plastic tubes.
Chromatography
LM985 was measured in plasma by an HPLC
method described by Kerr et al. (1985). A
Lichrosorb RP-8 column was used (Merck/BDH,
Poole, Dorset) with a C8 pre column. An isocratic
mobile phase of 12.5% methanol, 12.5%
acetonitrile, 12.5% isopropanol, 62.5% 0.005 M
phosphoric acid was pumped at a constant flow
rate of 1.5ml min-1 using a Waters (WatersPHARMACOKINETICS AND ANTI-TUMOUR ACTIVITY OF LM985 597
Associates, Norwich, UK) 6000A pump. An ion-
pair reagent, tetrabutylammonium-phosphate
(Sigma), was added (1.5mmoll-1). This both
improved chromatography and reduced retention
times from 21 min to 3.3min (LM985). The
injection volume was 10p1 and detection was at
303 nm using a Waters Lambda-Max 480 LC
spectrophotometer.
Two standard curves were prepared by the
addition of LM985 and LM975 to control human
plasma and plotting ratios of peak areas of the two
compounds to the internal standard against drug
concentration. This procedure was carried out in
human plasma as it was not possible to detect
LM985 in mouse plasma (see Results) but control
mouse plasma was analysed and no interfering
peaks were found. Peaks were traced and integrated
with an Isaac Model 42A data module (Cyborg
Corporation, USA), an Apple IIE computer (Apple
Computers Inc., USA) and Appligration II software
(Dynamic Solutions Corporation, USA). The curves
were linear over the range 0.1-40 pgml- . The
assay was sensitive to drug concentration at
lOngml-1. The concentration of LM985 and its
metabolite were determined from their peak area
ratios to the internal standard. Recovery was
>90% and the coefficient of variation for replicate
samples at a concentration of 5pgml-1 was 6.4%.
Confirmation of identity of LM975 in mouse
plasma was achieved by measuring retention
characteristics using two further column packing
materials viz. Hypersil C18 octadecyl-bonded silica
250 x 4.6 mm (Shandon Southern Instruments,
Cheshire, UK) and SAS Hypersil methyl-bonded
silica 100 x4.6 mm (Shandon Southern).
In vitro stability studies
Human plasma used in these studies was from our
stock plasma stored at -20°C. Two millilitres of
plasma with a plasma concentration of mgml1
LM985 (equivalent to peak plasma levels in the
mouse of LM975 after 1 h) was incubated at 37°C,
50p1 samples were taken and 900pl acetate buffer
and 100 p1 of internal standard were immediately
added to stop the reaction. LM985 and LM975
were then extracted using the Bond-Elut cartridges
and 10 p1 of the eluent injected into the HPLC.
Similar stability studies with LM985 in mouse
plasma and whole blood showed immediate
hydrolysis of LM985 to LM975. LM985 was shown
to be stable in mouse plasma at an acid pH.
Pharmacokinetic analysis
The area under the plasma concentration versus
time curve (AUC) was calculated using the
trapezoid rule.
Results
LM985 had no effect against MAC 15A grown as
an ascites tumour (Table II). When MAC 15A cells
were grown subcutaneously significant anti-tumour
effects were seen (Table III). Chemosensitivity of
established tumours treated on day 9 was
significantly greater than those treated on day 2.
Single dose LM985 above 200mgkg-1 showed only
moderate activity against MAC 13 s.c. tumours
whereas responses were considerably enhanced by
repeated injection 7 days later (Table IV). Maximum
tolerated dose (400mgkg-1) produced a significant
growth delay against the well-differentiated slower
growing MAC 26 tumours (Figure 2) and repeated
injection at this dose level 7 days later produced
cures.
Pharmacokinetic studies indicate a rapid
degradation of LM985 to LM975 in human plasma
at 37°C in vitro (Figure 3). Similar studies with
Table II Activity of LM985 against MAC 15A i.p.
Dose (mgkg 1)
Day 2 Day 9 Vehicle T/C% Activity
800 0.9% saline 23 toxic
400 400 0.9% saline 71 toxic
400 0.9% saline 107 0
200 200 0.9% saline 111 0
200 - 0.9% saline 92 0
100 100 0.9% saline 104 0
100 0.9% saline 100 0
Positive control Ethanol/
MethylCCNU arachis oil 154 1 +
20 (1/10)
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Table III Activity of LM985 against MAC 15A s.c.
Dose (mgkg-1)
Day 2 Day 9 Vehicle Survivors T/C% Activity
400 0.9% saline 10/10 51 1+
400 400 0.9% saline 5/10 14 toxic
400 0.9% saline 10/10 18 3+
Control - 10/10
Table IV Activity of LM985 against MAC 13
Dose (mgkg- 1)
Day 2 Day 9 Vehicle Survivors T/C% Activity
800 0.9% saline 0/10 toxic
400 400 0.9% saline 9/10 9 4+
400 0.9% saline 10/10 40 2+
400 0.9% saline 10/10 28 2+
200 200 0.9% saline 10/10 45 2+
200 0.9% saline 10/10 78 0
100 100 0.9% saline 10/10 72 1 +
100 0.9% saline 10/10 68 1 +
Positive control Ethanol/













Figure 2 Activity of LM985 against MAC 26. (0 0
untreated control; 0 0 LM985 200mgkg-I day 0,
day 7, activity score 1+; * * LM985 400mgkg-
day 0, activity score 3+; A * LM985 400mgkg-1
day 0, day 7, activity score 4+.
Time (min)
Figure 3 Breakdown of LM985 to LM975 in human
plasma at 37°C in vitro at a concentration of 1 mgml -
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mouse plasma and whole blood indicated
immediate breakdown of LM985 to LM975, with
no detection of the former compound, despite
extraction procedures commencing within 20sec of
its addition to the plasma.
Analysis of mouse plasma following 3 in vivo
dose levels of LM985 indicates a dose relationship
between AUC's for LM975 and the adminitered







Figure 4 Mouse plasma levels (±s.d.) of LM975
following i.p. injection of different in vivo dose levels
of LM985. A A 100mgkg-' AUC 0.95+0.26
(s.e.) mghml-1, 0 0 200mgkg-1 AUC
2.1+0.31mghml-1, *0E 400mgkg-1 AUC
3.89+0.54mghml 1.
Discussion
This investigation demonstrates that LM985 has
significant anti-tumour activity in a panel of
transplantable mouse colon tumours in mice thus
confirming the activity previously seen in colon 38.
Single i.p. injection at maximum tolerated dose
showed no activity against ascitic MAC 15A,
moderate activity against MAC 13 and sub-
cutaneous MAC 15A and produced a significant
growth delay against MAC 26. These latter
responses were considerably enhanced by repeated
injection 7 days later when greater than 90%
tumour inhibition was seen in MAC 13 and cures
were seen in MAC 26. The activity (4+) against
MAC 26 is particularly impressive as the previous
best recorded response with this tumour line seen
with cyclophosphamide is 3+ i.e. a growth delay of
approximately 9 days or 80% tumour inhibition.
Cures have not previously been achieved in this
tumour line.
This observation perhaps gives an insight to
factors involved in tumour responses. By nature of
the treatment protocol employed for the MAC 26
line, tumours are well established with a good
vascular supply. Our basic screening protocol with
MAC 13 uses 2 day old tumours which will not be
as well established, whereas in the repeated
treatment protocol the tumours although smaller
than the controls were well established. Good
responses were also seen with tumours treated on
day 9 only, suggesting that the establishment of a
blood vascular system may be an important factor
in tumour responses to LM985.
Kerr et al. (1985) have suggested that the
hydrolysis product flavone acetic acid (LM975)
may in fact be the active principle of this agent. If
this product is produced in the serum it is unlikely
that an ascitic tumour would show any significant
level of response and this is in fact the case with
MAC 15A. Subsequent transplantation of this
tumour line in a subcutaneous site revealed that
these cells were sensitive.
Pharmacokinetic studies have confirmed the
rapid degradation of LM985 to LM975 in human
plasma in vitro. Similar studies with mouse plasma
and whole blood have indicated immediate break-
down of LM985 to LM975 in vitro. Analysis of
mouse plasma following different in vivo dose levels
of LM985 indicated a good dose relationship
between levels of LM975 and the administered dose
of LM985. Area under the curve values of LM975
show a good relationship with anti-tumour
response suggesting LM975 to be the active
principle. A phase I trial with LM985 has been
completed and results indicated that dose limiting
toxicity was acute reversible hypotension (Kerr et
al., personal communication). These authors
recommend that LM975 be considered for clinical
trial as they suggest that substantially higher doses
of LM975 can be given without dose limiting
cardiovascular toxicity. The observations in this
study would indicate that LM975 may be of value
in the management of cancer as the MAC system
has been shown to be a good model of human
disease with responses to standard agents only seen
close to maximum tolerated dose. These flavonoid
compounds are novel structures which may have
completely different mechanisms of action from
conventional agents and investigations are currently
being undertaken to determine factors involved in
their antitumour activity.
The authors acknowledge Professor A.F. Fell and Dr B.J.
Clark, School of Pharmaceutical Chemistry, University of
Bradford for providing further proof of the identity of
LM975.
The work was supported by the White Watson/Turner
Cancer Research Trust, Bradford.600 J.A. DOUBLE et al.
References
COWEN, D.M. DOUBLE, J.A. & COWEN, P.N. (1980). Some
biological characteristics of transplantable lines of
mouse adenocarcinoma of the colon. J. Natl Cancer
Inst., 64, 675.
DOUBLE, J.A. & BALL, C.R. (1975). Chemotherapy of
transplantable adenocarcinoma of the colon in mice.
Cancer Chemother. Rep., 59, 1083.
DOUBLE, J.A., BALL, C.R. & COWEN, P.N. (1975).
Transplantation of adenocarcinoma of the colon in
mice. J. Natl Cancer Inst., 54, 271.
GERAN, R.I., GREENBERG, N.H., MAcDONALD, M.M.,
SCHUMACHER, A.M. & ABBOT, B.J. (1972). Protocols
for screening chemical agents and natural products
against tumours and other biological systems (third
edition). Cancer Chemother. Rep., 3, 1.
HAVSTEEN, B. (1983). Flavonoids, a class of natural
products of high pharmacological potency. Biochem.
Pharmacol., 32, 1141.
KERR, D.J., KAYE, S.B., CASSIDY, J. & 6 others. (1985). A
clinical pharmacokinetic study of LM985 and LM975.
Br. J. Cancer, 52, 467.